Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

13 treatments under study, led by Cultured Thymus Tissue

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Phase 1 (1)
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Completed4
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT05329935RecruitingPrimary

Congenital Athymia Patient Registry

NCT01220531Not ApplicableCompletedPrimary

Thymus Transplantation Safety-Efficacy

NCT00579709Phase 1Completed

Thymus Transplantation With Immunosuppression

NCT00576836Phase 2Completed

Thymus Transplantation Dose in DiGeorge #932

NCT00579527Phase 1/2Completed

Phase I/II Thymus Transplantation With Immunosuppression #950

Showing all 5 trials

Research Network

Common Treatments

  • Cultured Thymus Tissue2
  • Tacrolimus1
  • Cultured Thymus Tissue Implantation And Parental Parathyroid Transplantation1
  • Cyclosporine1
  • Blood Draw1

Active Sponsors

  • Sumitomo Pharma Switzerland GmbH5
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)4
  • National Institutes of Health (NIH)4
  • National Institute of Allergy and Infectious Diseases (NIAID)4

Top Investigators

Related Conditions

  • Complete Digeorge Syndrome5
  • Digeorge Anomaly4
  • Digeorge Syndrome3
  • Complete Atypical Digeorge Syndrome1
  • Congenital Athymia1

Activity Timeline